Medicine useful in melasma
Phase 2
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2022/10/046862
- Lead Sponsor
- Ajmal Khan Tibbiya College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All skin types
Who signed written consent form
epidermal and mixed type melasma
Exclusion Criteria
Pregnant and lactating mothers
Women on OCPs
Patient on long term steroids
Patient who are not willing to avoid cosmetics during the treatment time period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction in the pigmentationTimepoint: 56 days
- Secondary Outcome Measures
Name Time Method 3 D scannerTimepoint: 56 days;Melasma area and severity indexTimepoint: 56 days